Fact checked by Nick Blackmer Compounded versions of semaglutide, the active ingredient in weight loss drugs like Ozempic and ...

Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen ...

The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...

In the first arrangement of its kind, Eli Lilly to connect patients through telemedicine to providers of Alzheimer’s drugs.

With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of ...

Decision ends pharmacies’ permission to prepare versions of GLP-1 hormone mimics Novo Nordisk’s semaglutide diabetes and weight ... last year when the FDA ended official shortages of Eli Lilly’s ...

single-dose pen.” The federal government has authorised a transition period for compounded versions of Eli Lilly’s Zepbound and Mounjaro. Compounded semaglutide, sold under Novo Nordisk’s ...

If you assume that Lilly ... of semaglutide products. This impacts the compounding pharmacies in a way, but what does this headline mean for especially the big pharma companies like Eli Lilly ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly outperform Eli Lilly’s ... CagriSema might answer Lilly’s competitive threat.

(The Hill) – A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ... from the shortage list semaglutide, the active ...